Minimal Change Disease: A Clinical Guide
Definition
Minimal Change Disease (MCD) is a formal histopathological diagnosis, meaning it can only be definitively confirmed by examining kidney tissue under a microscope. It is characterized by the sudden onset of nephrotic syndrome, yet a renal biopsy paradoxically reveals: 1) normal-appearing glomeruli on standard light microscopy, 2) a complete absence of immune protein deposits on immunofluorescence, and 3) the pathognomonic finding of widespread, diffuse effacement (or flattening) of podocyte foot processes when viewed under a powerful electron microscope (1, 3).
Due to the invasive nature of a biopsy and the overwhelming statistical probability of MCD being the cause of nephrotic syndrome in young children (70-90% of cases), a pragmatic clinical approach is adopted. A child between the ages of 1 and 12 with a typical presentation is presumptively diagnosed and treated. If they respond fully to corticosteroid treatment, they are assigned the clinical diagnosis of Steroid-Sensitive Nephrotic Syndrome (SSNS). In this context, SSNS acts as a reliable clinical surrogate for a histological diagnosis of MCD, justifiably deferring the need for a biopsy (2).
Epidemiology
In Malaysia, Minimal Change Disease represents a significant and noteworthy portion of adult primary glomerular disease. Data from the Malaysian Registry of Renal Biopsy (MRRB) has shown that MCD accounted for 32% of all primary glomerulonephritis diagnoses over a seven-year period. Furthermore, it was the single most common glomerular disease diagnosed in Malaysian adults in the decade preceding the most recent report (21, 25). This prevalence is substantially higher than the 10-15% typically reported in Western adult populations (1). This key epidemiological finding has direct implications for the house officer; in a Malaysian adult presenting with new-onset nephrotic syndrome, the pre-test probability of the cause being a highly treatable, non-scarring condition like MCD is considerably higher. This knowledge should inform initial patient counseling, allowing for a more optimistic, albeit provisional, outlook while awaiting definitive biopsy results.
Globally, MCD is overwhelmingly a disease of childhood, causing 70-90% of idiopathic nephrotic syndrome cases, with a peak incidence between the ages of 2 and 6 (2, 8). In this younger age group, there is a distinct male predominance with a ratio of approximately 2:1. Evidence also strongly suggests a higher incidence in individuals of Asian descent compared to Caucasians, pointing to a likely interplay of genetic predisposition and environmental factors (14, 5).
Etiology
While the vast majority of MCD cases, particularly in children, are primary (or idiopathic) with no identifiable cause, a crucial subset of cases are secondary to other conditions. Identifying a secondary cause is a critical clinical task, as treating the underlying trigger can lead to the resolution of the nephrotic syndrome. These secondary associations are significantly more common in the adult population (3, 4).
Primary (Idiopathic): This is the default diagnosis in most children and many adults. It is presumed to arise from a complex, multifactorial process involving genetic susceptibility and an environmental or infectious trigger that incites the underlying immune dysregulation (3).
Secondary Causes:
Drugs: A meticulous drug history is mandatory in any adult with new-onset nephrotic syndrome.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): This is the most frequently implicated drug class. The association is not just with MCD but also with a distinct syndrome of nephrotic syndrome and acute interstitial nephritis (4).
Other Medications: A range of other drugs have been linked, including lithium, certain antibiotics (e.g., rifampicin, ampicillin), pamidronate, and, more recently, immune checkpoint inhibitors used in oncology (4).
Malignancy: MCD can be a paraneoplastic syndrome, where the immune response mounted against a tumor cross-reacts with components of the podocyte.
Hodgkin Lymphoma: This is the classic and strongest association. The onset of nephrotic syndrome can predate the diagnosis of the lymphoma by months, making it a vital diagnostic clue (2).
Other Cancers: Non-Hodgkin lymphoma, leukemia, and occasionally solid tumors like lung or colon cancer have also been linked, especially in older adults (2).
Infections: Various infectious agents are thought to act as triggers for the immune dysregulation that drives MCD. Common viral upper respiratory tract infections frequently precede relapses in children. More specific associations have been noted with syphilis, HIV, and hepatitis C (2).
Allergies and Atopy: A strong clinical association exists between MCD and atopic conditions like eczema, asthma, and allergic rhinitis. Relapses are frequently reported following exposure to specific allergens such as pollen, house dust mites, insect bites, or certain foods (e.g., dairy, soy). This link provides compelling support for the hypothesis that MCD is driven by a Th2-type immune response, the same pathway that underpins allergic reactions (4).
Pathophysiology
MCD is fundamentally a podocytopathy, a primary disorder of the glomerular visceral epithelial cell, or podocyte. These highly specialized cells form the final layer of the glomerular filtration barrier, and their health is essential for preventing protein loss (1). The disease is driven by a profound but reversible immune dysregulation that leads to a structural and functional failure of this barrier.
The core mechanism is a direct or indirect insult that causes the podocytes' intricate, interdigitating "foot processes" to retract, flatten, and fuse—a dramatic ultrastructural change known as diffuse effacement. This is the absolute pathognomonic finding on electron microscopy. This effacement leads to the physical dismantling of the slit diaphragm, a specialized cell-cell junction that spans the space between foot processes and acts as the ultimate size- and charge-selective barrier to protein. The loss of this barrier allows massive amounts of albumin and other proteins to leak from the blood into the urine (1).
While historically considered a T-cell mediated disorder where a mysterious "circulating permeability factor" was released, the paradigm has shifted significantly. Recent landmark discoveries strongly implicate B-cells and humoral immunity in the disease process. The most compelling evidence is the identification of autoantibodies targeting nephrin, a critical transmembrane protein that forms the backbone of the slit diaphragm, in patients with active MCD (5, 7). The theory is that these antibodies bind directly to nephrin on the podocyte surface, triggering a cascade of intracellular signals that leads to cytoskeletal collapse and foot process effacement. The clinical success of Rituximab, a monoclonal antibody that specifically depletes CD20-positive B-cells, in treating difficult, relapsing MCD provides powerful in-vivo evidence for the central role of B-cells in the disease's pathogenesis (6).
Clinical Presentation
The presentation of MCD is that of classic nephrotic syndrome, which is often characterized by a remarkably rapid and dramatic onset over days to weeks (4).
Diagnostic Clues: The hallmark is the abrupt onset of significant, generalized edema in an otherwise healthy child or adult. Patients or their parents will often report that the urine has become persistently frothy or foamy, a direct result of the high protein content reducing its surface tension (9).
Common Symptoms (>50%):
Pitting Edema: This is the cardinal sign. It typically starts in gravity-dependent areas like the ankles and shins and is often most prominent in the periorbital region upon waking, giving a "puffy-eyed" appearance. As it progresses, it can become generalized (anasarca), leading to taut skin, large ascites, significant scrotal or labial swelling, and pleural effusions (8).
Frothy Urine (9)
Fatigue, malaise, and lethargy.
Less Common Symptoms (10-50%):
Abdominal pain or a feeling of fullness, often due to the stretching of the abdominal wall by ascites or, more ominously, peritonitis.
Dyspnea on exertion or at rest, caused by large pleural effusions compressing the lungs.
Significant weight gain over a short period, entirely due to fluid retention.
⚠️ Red Flag Signs & Symptoms: These indicate a medical emergency requiring immediate assessment and intervention.
Fever with abdominal tenderness: In a child with ascites, this is Spontaneous Bacterial Peritonitis (SBP) until proven otherwise. This is a life-threatening infection requiring urgent diagnostic paracentesis and empiric antibiotics (33).
Unilateral leg swelling, pleuritic chest pain, or sudden shortness of breath/tachycardia: These are classic signs of thromboembolism (DVT or PE, respectively) and warrant immediate investigation (4).
Reduced urine output (oliguria) or a rapidly rising creatinine: This indicates the development of Acute Kidney Injury (AKI), a complication that is more common in adults and requires careful fluid management (8).
Complications
The nephrotic state is a systemic condition fraught with dangerous complications that a house officer must actively prevent, monitor for, and manage.
Thromboembolism: Nephrotic syndrome is one of the most potent acquired hypercoagulable states. This is caused by a multifactorial imbalance in the hemostatic system, including urinary loss of key anticoagulant proteins (like Antithrombin III and Protein S) and a reactive hepatic overproduction of prothrombotic factors (like fibrinogen, Factor V, and Factor VIII). This places patients at a very high risk for deep vein thrombosis (DVT), pulmonary embolism (PE), and the particularly feared renal vein thrombosis (4).
Infections: Patients are severely immunocompromised and highly susceptible to bacterial infections, particularly from encapsulated organisms like Streptococcus pneumoniae and Haemophilus influenzae. This vulnerability stems from the profound urinary loss of immunoglobulins (IgG) and complement factors (such as Factor B), which are essential for opsonizing bacteria for phagocytosis. Spontaneous Bacterial Peritonitis (SBP) is a classic and feared complication in children with ascites (11).
Acute Kidney Injury (AKI): This is more common in adults and can be caused by several mechanisms. The most frequent is severe intravascular volume depletion ("pre-renal azotemia") from profound hypoalbuminemia. However, it can also result from acute tubular necrosis due to severe interstitial edema or, in cases where NSAIDs are the trigger, an associated acute interstitial nephritis (8).
Hyperlipidemia and Accelerated Atherosclerosis: The liver's response to low albumin includes a massive overproduction of lipoproteins, leading to markedly elevated levels of total cholesterol, LDL, and triglycerides. While a short-term issue, prolonged or frequently relapsing nephrotic syndrome significantly increases the long-term risk of accelerated atherosclerosis and cardiovascular events (4).
Prognosis
Despite the severity of its presentation and complications, the overall renal prognosis for MCD is excellent. The disease does not typically cause permanent glomerular scarring, and the risk of progression to end-stage kidney disease is very low (4). A very high percentage of patients achieve complete remission with initial corticosteroid therapy: over 90% of children and 80-90% of adults (3, 7).
The main challenge in MCD is not kidney failure, but managing the disease's tendency to relapse. Relapses are common, affecting over 80% of initial responders. A significant subset of these patients will go on to develop a more challenging disease course, defined as either Frequently Relapsing Nephrotic Syndrome (FRNS) (two or more relapses in 6 months, or four or more in 12 months) or Steroid-Dependent Nephrotic Syndrome (SDNS) (relapsing while on tapering steroids or within 14 days of stopping). These patients require long-term immunosuppression and face cumulative morbidity from both the disease and its treatment (8, 12).
Differential Diagnosis
In an adult, new-onset nephrotic syndrome requires a broad differential, making a biopsy essential. In children, the list is narrower but crucial to consider in atypical presentations.
Focal Segmental Glomerulosclerosis (FSGS): This is the most important differential, especially in adults and steroid-resistant children. Like MCD, it is a podocytopathy, but it is defined by irreversible scarring (sclerosis) in segments of some glomeruli. The clinical presentation can be identical, but patients with FSGS are more likely to have hypertension, microscopic hematuria, and impaired renal function at presentation. Some pathologists consider MCD and primary FSGS to be part of a single spectrum of podocyte injury. A biopsy is the only way to definitively distinguish FSGS from MCD (13).
Membranous Nephropathy: This is a very common cause of nephrotic syndrome in older Caucasian adults. It is an immune-complex disease caused by antibodies (often against the PLA2R antigen) that deposit on the outside of the glomerular basement membrane. While it presents with full-blown nephrotic syndrome, the onset is often more insidious than the abrupt edema of MCD. A biopsy showing thickened glomerular basement membranes ("spikes") and granular immune deposits on immunofluorescence is diagnostic (13).
Lupus Nephritis (Class V): In any patient, but particularly a young female, with other systemic features (e.g., malar rash, photosensitivity, arthritis, cytopenias), Systemic Lupus Erythematosus (SLE) must be a prime consideration. The presence of a positive ANA and anti-dsDNA, along with low serum complement levels (C3/C4), would strongly point away from primary MCD, where complement levels are characteristically normal (11).
Amyloidosis: In an older adult, particularly one with evidence of other organ involvement (e.g., restrictive cardiomyopathy, macroglossia, peripheral neuropathy), renal amyloid deposition should be considered. A biopsy with Congo red staining showing apple-green birefringence under polarized light is diagnostic.
Investigations
The workup is aimed at confirming the presence and severity of nephrotic syndrome, assessing for complications, screening for secondary causes, and, in adults, preparing for a definitive biopsy.
Immediate & Bedside Tests
Urine Dipstick: This is the essential first step to confirm heavy proteinuria (typically reading 3+ or 4+). The absence of significant blood is a key feature of the "bland" or "non-nephritic" urinary sediment that is characteristic of pure MCD (11).
Diagnostic Workup
First-Line Investigations:
Urine Protein:Creatinine Ratio (UPCR): A spot urine sample provides a convenient and accurate way to quantify the degree of proteinuria, which is essential for diagnosis and for monitoring response to treatment. A ratio >200 mg/mmol in children or >300 mg/mmol in adults is consistent with nephrotic-range proteinuria (12).
Core Blood Tests:
Serum Albumin: To confirm and quantify the severity of hypoalbuminemia (typically <25 g/L), a key diagnostic criterion and a driver of complications (11).
Renal Profile: To establish a baseline creatinine and to detect the presence of Acute Kidney Injury (AKI) (10).
Lipid Panel: To confirm the presence of hyperlipidemia (11).
Full Blood Count (FBC): To check for hemoconcentration (an elevated hematocrit) and thrombocytosis (an elevated platelet count), both of which are useful markers of intravascular volume depletion and increased thrombotic risk (11).
Gold Standard:
Renal Biopsy: This is the definitive diagnostic test that establishes the diagnosis of MCD. It is considered mandatory for virtually all adults with new-onset nephrotic syndrome to rule out other pathologies. It is reserved for children with atypical features (e.g., age of onset <1 or >12 years, resistance to steroid therapy, persistent hypertension or hematuria, low serum complement) (2). The diagnosis requires the classic triad: normal light microscopy, negative immunofluorescence, and diffuse foot process effacement on electron microscopy (1).
Monitoring & Staging
Home Urine Monitoring: This is the cornerstone of long-term management and relapse detection. Patients or their parents are taught to monitor the first-morning urine sample with a simple dipstick. A reading of 2+ or greater for three consecutive days is the standard definition of a relapse and should trigger prompt initiation of treatment, often preventing the need for hospitalization (33).
Management
In the absence of specific Malaysian clinical practice guidelines for nephrotic syndrome, management is guided by internationally recognized recommendations, most notably those published by KDIGO (Kidney Disease: Improving Global Outcomes) (39, 40). The primary goals are to induce complete remission of proteinuria, manage the severe systemic complications, and crucially, to minimize the cumulative toxicity of long-term treatment.
Management Principles
The management of MCD is a dual-track process that focuses on inducing remission of the underlying immune process with immunosuppression while simultaneously providing meticulous and vigilant supportive care to manage the life-threatening complications of the nephrotic state. Patient and family education on diet, medication adherence, and relapse detection is paramount.
Acute Stabilisation (The First Hour)
While most patients are hemodynamically stable, those presenting with signs of severe intravascular volume depletion (hypotension, tachycardia, poor perfusion) require careful and urgent resuscitation. This requires navigating the "swollen but dry" paradox.
Circulation: If the patient shows signs of hypovolemic shock, the immediate priority is to restore intravascular volume.
Administer a bolus of 20% Human Albumin Solution (1 g/kg) infused over 4 hours (the action). This hyperoncotic solution works to pull fluid from the edematous interstitium back into the vascular space, thereby restoring circulatory volume, improving organ perfusion, and increasing the delivery of diuretics to the kidneys (the rationale) (33). Aggressive diuresis before volume restoration is dangerous and can worsen AKI and thrombosis risk.
Definitive Therapy
First-Line Treatment: Corticosteroids
Children: The standard KDIGO-recommended regimen is oral Prednisolone 60 mg/m²/day (max 60mg) for 4-6 weeks to induce remission. This is followed by a tapering phase of 40 mg/m² on alternate days for another 4-6 weeks (33).
Adults: The dose is oral Prednisolone 1 mg/kg/day (max 80mg). Adults typically respond more slowly, so the initial daily course often continues for up to 16 weeks, or until remission is achieved, before a very slow taper over several months is initiated (7).
Second-Line/Escalation (for Frequent Relapsers/Steroid-Dependence):
To avoid the significant toxicity of long-term high-dose steroids (e.g., cushingoid features, growth failure, osteoporosis, cataracts), a steroid-sparing agent is introduced. The choice is individualized.
Cyclophosphamide: An alkylating agent used for a short, finite course (8-12 weeks) that can induce a durable, long-term remission. Requires monitoring for bone marrow suppression and has risks of infertility (10).
Calcineurin Inhibitors (e.g., Cyclosporine, Tacrolimus): Highly effective at maintaining remission but are often "remission-holding" rather than "remission-inducing." They require close monitoring for nephrotoxicity, hypertension, and metabolic side effects (10).
Rituximab: A monoclonal antibody that depletes B-cells. It is a highly effective agent reserved for severe, multi-relapsing, or CNI-dependent cases and has revolutionized the management of difficult MCD. It can induce prolonged, drug-free remission (10).
Supportive & Symptomatic Care
This is the cornerstone of daily ward-level management and is a critical role for the house officer.
Edema Management:
Strict No-Added-Salt Diet (<2 g/day sodium) and, if hyponatremic, fluid restriction.
Diuretics: High-dose IV Furosemide is often required. For refractory edema associated with severe hypoalbuminemia (<20 g/L), the "albumin-furosemide sandwich" is a key technique: an infusion of 20% albumin is given to pull fluid into the vessels, with IV furosemide administered mid-way through and after the infusion to excrete the mobilized fluid (33).
Anticoagulation: Prophylactic anticoagulation is not routine for a first presentation but should be strongly considered in high-risk adults (e.g., serum albumin <20 g/L, prolonged immobility, central venous line, prior thrombosis) to prevent DVT/PE (4).
Infection Prevention: Ensure all routine vaccinations are up-to-date prior to starting immunosuppression. Live vaccines (e.g., MMR, Varicella, BCG) are strictly contraindicated while patients are on high-dose immunosuppression (33).
Key Nursing & Monitoring Instructions
Strict daily weights taken at the same time each day; this is the best measure of fluid balance.
Meticulous input/output chart monitoring.
Monitor blood pressure at least 4-hourly, checking for both hypertension and hypotension.
Inform medical staff immediately if urine output is <0.5mL/kg/hr, or if the patient develops fever, abdominal pain, or any signs of thrombosis.
Provide meticulous skin care to prevent breakdown in severely edematous areas.
When to Escalate
Call Your Senior (MO/Specialist) if:
The patient develops any red flag signs (fever with abdominal pain, signs suggestive of DVT/PE).
The patient becomes hypotensive, tachycardic, or develops severe AKI (e.g., oliguria or rapidly rising creatinine).
You are considering the use of IV albumin for severe or refractory edema.
The patient's blood pressure is difficult to control.
Referral Criteria:
All adults with new-onset nephrotic syndrome require prompt referral to the Nephrology team for consideration of biopsy and long-term management.
All children with nephrotic syndrome should be managed in consultation with a General Paediatrician or Paediatric Nephrologist from the outset.
References
Vivarelli, M., Massella, L., Ruggiero, B., & Emma, F. (2017). Minimal Change Disease. Clinical Journal of the American Society of Nephrology, 12(2), 332–345. https://cjasn.asnjournals.org/content/12/2/332
Kazi, J. I., & Mubarak, M. (2021). Minimal Change Disease: A Review. Southern Medical Journal, 114(7), 443-448. https://sma.org/southern-medical-journal/article/minimal-change-disease-a-review/
Hassler, J. R. (2020). Minimal Change Disease. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK560639/
UNC Kidney Center. (n.d.). Minimal Change Disease. https://unckidneycenter.org/kidneyhealthlibrary/glomerular-disease/minimal-change-disease/
Bertelli, R., Bonanni, A., Caridi, G., & Ghiggeri, G. M. (2021). Molecular Mechanisms of Proteinuria in Minimal Change Disease. Frontiers in Medicine, 8, 761600. https://www.frontiersin.org/articles/10.3389/fmed.2021.761600/full
Hogan, J., & Radhakrishnan, J. (2017). Clinical trials in minimal change disease. Nephrology Dialysis Transplantation, 32(suppl_1), i7–i13. https://academic.oup.com/ndt/article/32/suppl_1/i7/2930784
Sparks, M. A. (2025). #NephMadness 2025: Minimal Change Disease Region. AJKD Blog. https://ajkdblog.org/2025/03/01/nephmadness-2025-minimal-change-dz-region/
Wikipedia. (2024). Minimal change disease. https://en.wikipedia.org/wiki/Minimal_change_disease
American Kidney Fund. (n.d.). Minimal change disease. https://www.kidneyfund.org/all-about-kidneys/other-kidney-diseases/minimal-change-disease
Merck Manual Professional Version. (n.d.). Minimal Change Disease. https://www.merckmanuals.com/professional/genitourinary-disorders/glomerular-disorders/minimal-change-disease
Gul, U., & Motiwala, A. (2023). Nephrotic Syndrome. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470444/
Ismail, I., & Abdul Gafor, A. H. (2019). Parental Knowledge on Nephrotic Syndrome and Disease Relapse in children. Medical Journal of Malaysia, 74(4), 323-328. https://www.e-mjm.org/2019/v74n4/nephrotic-syndrome.pdf
Kodner, C. (2016). Diagnosis and Management of Nephrotic Syndrome in Adults. American Family Physician, 93(6), 479-484. https://www.aafp.org/pubs/afp/issues/2016/0315/p479.html
NephCure Kidney International. (n.d.). Minimal Change Disease (MCD). https://nephcure.org/intro-to-rkd/types-of-rkd/minimal-change-disease-mcd/
Lim, Y. N., et al. (2018). Primary Focal Segmental Glomerulosclerosis and Minimal Change Disease as one Spectrum of Disease. Malaysian Journal of Medicine and Health Sciences, 14(3), 29-35. https://medic.upm.edu.my/upload/dokumen/2018092410535113_MJMHS_Oct_2018.pdf
Malaysian Society of Nephrology. (2021). 28th Report of the Malaysian Registry of Renal Biopsy: Chapter 2 Primary Glomerulonephritis. https://www.msn.org.my/nrr/wp-content/uploads/2023/01/MRRB-Report_Chapter-2_edited-Rosna_19-Dec-2021_.pdf
The Royal Children's Hospital Melbourne. (2021). Clinical Practice Guidelines: Nephrotic syndrome. https://www.rch.org.au/clinicalguide/guideline_index/nephrotic_syndrome/
Malaysian Society of Nephrology. (n.d.). Guidelines. https://msn.org.my/guidelines/
Kidney Disease: Improving Global Outcomes (KDIGO). (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. https://kdigo.org/guidelines/gd/
